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Edited by Laszlo NagyAbstract The purpose of this study was to inhibit endotoxin
induced cytokines production and liver injury by liver non-paren-
chymal cell (NPC) selective delivery of nuclear factor jB
(NFjB) decoy using mannosylated cationic liposomes (Man-lip-
osomes). In this study, we examined the distribution, inhibitory
eﬀect on cytokines production and ALT/AST of intravenously
injected Man-liposome/NFjB decoy complex. Man-liposome/
[32P] NFjB decoy complexes mostly accumulated in the liver,
preferentially in NPC. In a murine lipopolysaccharide-induced li-
ver failure model, the production of tumor necrosis factor-a
(TNFa), IFNc, IL1-b, ALT and AST were eﬀectively reduced
by Man-liposome complexes. However, cationic or galactosy-
lated cationic liposome complexes could not inhibit TNFa
production.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords:Mannosylated cationic liposome;Mannose receptor;
NFjB decoy; Macrophage; Tumor necrosis factor-a1. Introduction
Endotoxin syndrome is a particularly grave complication be-
cause bacteriologically proven infection occurs in up to 80% of
patients with hepatic failure [1]. It is known that endotoxin
syndrome, caused by infection of gram-negative bacteria, is a
systemic inﬂammatory response mediated by several cytokines
including tumor necrosis factor-a (TNFa), IL-1b, IFNc, IL-
12, etc., through nuclear factor jB (NFjB) activation in vivo
[2]. Furthermore, increasing evidence indicates that Kupﬀer
cells, hepatic resident macrophages, play a pivotal role in the
production of the inﬂammatory cytokine response under a
variety of stress conditions, such as hepatic failure, including
viral infection [3,4]. Therefore, the prevention of cytokine
overproduction by Kupﬀer cells would be an important factor
for the treatment of endotoxin syndrome.Abbreviations: TNFa, tumor necrosis factor-a; LPS, lipopolysaccha-
ride; NFjB, nuclear factor jB; PC, parenchymal cell; NPC, non-par-
enchymal cell
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doi:10.1016/j.febslet.2006.05.059Several reports have demonstrated that NFjB activation in
macrophages causes inﬂammatory cytokines and adhesionmol-
ecule production in a wide variety of types of inﬂammation and
disease [5,6]. Recently Wrighton et al. [7] and Foxwell et al. [8]
reported that adenoviral gene transfer of super-repressor IjB
produced eﬀective suppression of NFjB, however, the inﬂam-
matory reaction and high immunogenesity of the adenoviral
vector itself posed a serious obstacle to in vivo therapy. In con-
trast, the decoy strategy has been developed and considered a
useful tool as a new class of anti-gene strategy. In this NFjB de-
coy, double stranded oligonucleotides containing NFjB bind-
ing sequences, bind to activated-NFjB consequently
inhibiting transcription by NFjB [9–11]. Therefore, the NFjB
decoy approach enables us to treat diseases by suppression of
target gene expression without high immunogenisity [12].
To establish NFjB decoy therapy, it is necessary to develop
a Kupﬀer cell-targeting carrier for NFjB decoy to treat liver
disease because of the low accumulation in Kupﬀer cells after
intravenous injection of NFjB decoy [13]. As far as the liver-
speciﬁc delivery of NFjB decoy is concerned, Ogushi et al. [14]
recently demonstrated that NFjB decoy, transferred by fusi-
genic liposomes with hemagglutinating virus of Japan (HVJ
liposomes) from the portal vein, eﬀectively suppressed endo-
toxin-induced fatal liver injury in mice. However, intraportal
injection is diﬃcult in clinical situations because it needs a skil-
ful surgical technique and increases the burden on the patient.
Although intravenous injection is the most simple method,
HVJ liposomes cannot accumulate in the liver following intra-
venous injection, because HVJ liposomes fuse to cells in a non-
speciﬁc manner [15,16]. As a consequence, oligonucleotide is
non-speciﬁcally delivered by HVJ liposomes to the lung, spleen
and kidneys after intravenous injection [16]. In fact, Ogushi
et al. achieved a therapeutic eﬀect only by intraportal injection
of HVJ liposomes not by intravenous injection. Moreover, be-
cause Kupﬀer cells account for only 15% of the total liver cells
[17], non-speciﬁc fusion with HVJ liposomes would cause an
increase in the NFjB decoy dose. Furthermore, preparing
HVJ liposomes is complicated with irradiation to remove viral
toxicity and centrifugation to remove free HVJ, etc. [18].
Therefore, a Kupﬀer cell-targeting carrier for NFjB decoy
would lead to a more eﬀective treatment for lipopolysaccharide
(LPS) induced liver injury.
To develop a Kupﬀer cell-speciﬁc targeting carrier for
NFjB decoy, receptor-mediated uptake is a promisingation of European Biochemical Societies.
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large numbers of mannose receptors on their surface [17].
Recently we designed cholesten-5-yloxy-N-{4-[(1-imino-2-D-
thiomannosyl-ethyl)-amino]butyl} formamide (Man-C4-Chol)
to prepare mannosylated cationic liposomes (Man-liposomes)
for mannose receptor-mediated plasmid DNA (pDNA) deliv-
ery [20–23]. Man-C4-Chol can be stably incorporated into
liposomes and easily recognized by mannose receptors under
in vivo conditions [24]. Furthermore, because Man-C4-Chol
has an amino group for binding to pDNA via electrostatic
interaction and a mannose residue for recognition by man-
nose receptors, a high density of mannose residues can be
provided on the surface of liposome without aﬀecting the
binding ability of the cationic liposomes to pDNA [20]. Fur-
thermore, we demonstrated that the highest gene expression
observed for pDNA complexed with Man-liposomes via
mannose receptor-mediated endocytosis [25].
Since NFjB decoy has anionic charges on its surface, we
believe that NFjB decoy could form a complex with cationic
liposome mediated by electrostatic interaction. In addition,
since the size of NFjB decoy (20 base pairs) was more than
300-times smaller than pDNA (about 7000 base pairs), a
large amount of NFjB decoy could form a complex with
Man-liposomes. In this respect, a smaller amount of Man-
liposomes could eﬀectively deliver NFjB decoy compared
with pDNA delivery. The reduction in the dose of carrier
would be attractive for clinical therapy because of the re-
duced side-eﬀects and low cost. The purpose of this study
was to establish decoy therapy for endotoxin-induced liver
disease. We developed a potential carrier for Kupﬀer cell tar-
geting delivery of NFjB decoy after intravenous injection,
demonstrating the ﬁrst in vivo therapy by targeted delivery
of NFjB decoy via intravenous injection. Results were com-
pared with naked NFjB decoy and its complex with bare
cationic liposomes.2. Materials and methods
2.1. Materials
N-(4-aminoethyl) carbamic acid tert-butyl ester and N-[1-(2,3-dio-
leyloxy)propyl]-n,n,n-tri-methylammonium chloride (DOTMA) were
purchased from Tokyo Kasei Kogyo Co. Ltd. (Tokyo, Japan). Diol-
eoylphosphatidylethanolamine (DOPE) was purchased from Avanti
Polar Lipids Inc. (Alabaster, AL, USA). Cholesteryl chloroformate,
heparin LPSs (from salmonella enterica serotype Minnesota Re 595)
and collagenase were purchased from Sigma Chemicals Pty. Ltd. (St.
Louis, MO, USA). Oligonucleotides (NFjB decoy: 5 0-AGTTGAG-
GGGACTTTCCCAGGC-3 0, 5 0-GCCTGGGAAAGTCCCCTCA-
ACT-3 0; random decoy: 5 0-TTGCCGTACCTGACTTAGCC-3 0,
5 0-GGCTAAGTCAGGTACGGCAA-30) were purchased from Oper-
on Biotechnologies Inc. (Tokyo, Japan). Ethylene glycol-bis(b-amino-
ethylether)-N,N,N 0,N 0-tetraacetic acid (EGTA), Clear-Sol I and
cholesterol were purchased from Nacalai Tesque Inc. (Kyoto, Japan).
MEGALABEL 5 0-End Labeling Kit was purchased from Takara Bio
Inc. (Shiga, Japan). Soluene-350 was purchased from Perkin–Elmer
Inc. (Boston, MA, USA). NAP-5 column was purchased from Amer-
sham Biosciences Co. (Piscatway, NJ, USA). Trypan blue was pur-
chased from Invitrogen Co. (Grand Island, NY, USA). Mouse
TNFa BD OptEIA ELISA Kit was purchased from Becton, Dickin-
son and Company (Mississauga, Canada). Fraction-PREP Nuclear/
Cytosol Fraction Kit was purchased from BioVision Inc. (Mountain
View, CA, USA). Transaminase C II test wako was purchased from
Wako Pure Chemical Industries Ltd. (Osaka, Japan). Chemilumines-
cent NFjB Activation Assay Kit was purchased from Oxford Biomed-
ical Research Inc. (Oxford, MI, USA).2.2. Animals
Female ICR mice (5-week old, 22–24 g) or female C57BL/6 mice (6-
week old, 18–20 g) were obtained from Shizuoka Agricultural Co-
operative Association for Laboratory Animals (Shizuoka, Japan).
All animal experiments were carried out in accordance with the Prin-
ciples of Laboratory Animal Care as adopted and promulgated by
the US National Institutes of Health and with the Guidelines for
Animal Experiments of Kyoto University.
2.3. Radiophosphorylation of decoy oligonucleotides
Annealed NFjB decoy were labeled with [c-32P] ATP using
MEGALABELTM 5 0-End Labeling Kit with some modiﬁcation as re-
ported previously [13]. Brieﬂy, oligonucleotides, [c-32P] ATP and T4
polynucleotide kinase were mixed in phosphorylation buﬀer. After
30 min incubation at 37 C, the mixture was incubated for 10 min at
70 C in order to inactivate T4 polynucleotide kinase. Then, the mix-
ture was puriﬁed by gel chromatography using a NAP 5 column and
eluted with 10 mM Tris–Cl and 1 mM EDTA (pH 8.0). The fractions
containing derivatives were selected based on their radioactivity.
2.4. Synthesis of Man-C4-Chol
Man-C4-Chol was synthesized as reported previously [20]. Brieﬂy,
cholesteryl chloroformate and N-(4-aminobutyl)carbamic acid tert-bu-
tyl ester were reacted in chloroform for 24 h at room temperature. A
solution of triﬂuoroacetic acid and chloroform was added dropwise
and the mixture was stirred for 4 h at 4 C. The solvent was evaporated
to obtain N-(4-aminobutyl)-(cholesten-5-yloxyl)formamide which was
then combined with 2-imino-2-methoxyethyl-1-thiomannoside and
the mixture was stirred for 24 h at room temperature. After evapora-
tion, the resultant material was suspended in water, dialyzed against
distilled water for 48 h (12 kDa cut-oﬀ dialysis tubing), and then
lyophilized. Gal-C4-Chol was also synthesized by the same method
using galactose instead of mannose.
2.5. Preparation of liposomes and their complex with NFjB decoy
Man-liposomes, Gal-liposomes or DOTMA/cholesterol liposomes
were prepared as reported previously [20]. Brieﬂy, Man-C4-Chol,
Gal-C4-Chol or DOTMA was mixed with DOPE or cholesterol,
respectively, in chloroform at a molar ratio of and the mixture was
dried, vacuum desiccated, and resuspended in sterile 5% dextrose.
After hydration, the dispersion was sonicated for 10 min in a bath
sonicator and then for 3 min in a tip sonicator to form liposomes.
The preparation of liposome/NFjB decoy complexes for in vivo use
was carried out by the method of Kawakami et al. [25]. Equal volumes
of NFjB decoy and stock liposome solution were diluted with 5% dex-
trose at room temperature. Then, the NFjB decoy solution was added
rapidly to the liposome solution and the mixture was agitated rapidly
by pumping it up and down twice in the pipet tip. The mixture was
then left at room temperature for 30 min. The theoretical charge ratio
of lipid/NFjB decoy was calculated as a molar ratio of Man-C4-Chol
(monovalent) to a nucleotide unit (average molecular weight 330)
[21,26,27].
The particle size of the liposomes and liposomes/NFjB decoy com-
plexes were measured using dynamic light scattering spectrophotome-
ter (LS-900, Otsuka Electronics, Osaka, Japan). The zeta potential of
liposomes and liposome/NFjB decoy complexes were measured by
Nano ZS (Malvern Instruments Ltd., Malvern, WR, UK).
2.6. In vivo distribution
In vivo distribution was examined as previously reported [13]. NFjB
decoy complexed with liposomes in 300 ll 5% dextrose solution was
intravenously injected into mice. Blood was collected from the vena
cava at 1, 5, 10, 30, 60 min, and mice were killed at each collection time
point. Liver, kidney, spleen, heart and lung were removed, washed
with saline, blotted dry, and weighed. Immediately prior to blood col-
lection, urine was also collected directly from the urinary bladder. 10 ll
of blood and 200 ll of urine, and a small amount of each tissue were
digested with Soluene-350 (0.7 ll for blood, urine and tissues) by incu-
bation overnight at 54 C. Following digestion, 0.2 ml isopropanol,
0.2 ml 30% hydroxyperoxide, 0.1 ml 5 M HCl, and 5.0 ml Clear-Sol I
were added. The samples were stored overnight, and radioactivity
was measured in a scintillation counter (LSA-500, Beckman, Tokyo,
Japan).
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Intrahepatic distribution of [32P] NFjB decoy complexed with Man-
liposomes was determined as in our previous report [24]. Five minutes
after intravenous injection of NFjB decoy, Man-liposome/NFjB de-
coy or cationic liposome/NFjB decoy complex, each mouse was anes-
thetized with diethyl ether and the liver was perfused with pre-
perfusion buﬀer (Ca2+, Mg2+-free Hanks buﬀer, pH 7.4, containing
1000 U/L heparin and 0.19 g/L EGTA) for 6 min at 5 ml/min followed
by Hanks buﬀer containing 5 mM CaCl2 and 220 U/ml collagenase
(Type I) (pH 7.4) for 6 min at 5 ml/min. After discontinuation of the
perfusion, liver was excised and liver cells were dispersed in ice-cold
Hanks-HEPES buﬀer. The cell suspension was ﬁltered through cotton
gauze, followed by centrifugation at 50 · g for 1 min at 4 C. The pellet
containing parenchymal cells (PC) was washed 4 times with ice-cold
Hanks-HEPES buﬀer. The supernatant containing non-parenchymal
cell (NPC) was collected and puriﬁed by centrifugation at 50 · g for
1 min at 4 C (4 times). PC and NPC suspensions were centrifuged
at 340 · g for 10 min. PC and NPC were then resuspended separately
in ice-cold Hanks-HEPES buﬀer (ﬁnal volume 2 ml). The cell number
and viability were determined by the trypan blue exclusion method.
The radioactivity of 500 ll of each cell suspension was measured by
the same method as for the in vivo distribution.
2.8. Animal treatment protocol
For cytokine secretion assessment, blood was collected from ICR
mice 1 h after intravenous injection of LPS (0.4 mg/kg). The blood
was allowed to coagulate for 2–3 h at 0.4 C and serum was isolated
as the supernatant fraction following centrifugation at 2000 · g for
20 min. The serum samples were immediately stored at 80 C. The
amounts of TNFa, IL-1b and IFN-c were analyzed using an Opti-
EIA ELISA Kit according to the manufacturer’s protocol. For se-
vere liver injury model, C57BL/6 mice were injected intraperitoneally
with LPS (0.05 mg/kg) and D-galactosamine (1000 mg/kg) in pyro-
gen-free saline. The blood was allowed to coagulate for 2–3 h at 4 C
and serum was isolated as the supernatant fraction following centrifu-
gation at 2000 · g for 20 min. Serum ALT and AST were measured
with transaminase C II test wako according to the manufacturer’s
protocol.
2.9. Enzyme immunoassay for determination of the amount of nuclear
NFjB
Liver was removed, washed with ice-cold saline, and blotted dry. A
small amount of liver was homogenized in phosphate-buﬀered saline.
Pellets of cells were obtained by centrifugation at 500 · g for 2 min,
and a nuclear extract was prepared using a Nuclear/Cytosol Fraction
Kit. The amounts of NFjB in the nuclei were measured with an NFjB
Activation Assay Kit according to the manufacturer’s protocol.
2.10. Statistical analysis
Statistical comparisons were performed by Student’s t test for two
groups and one-way ANOVA for multiple groups. Post hoc multiple
comparisons were made by using Turkey’s test.3. Results
3.1. Particle size and zeta potential of Man-liposomes and their
complex with NFjB decoy
Table 1 summarizes the mean diameter and zeta potential of
liposomes or liposome/NFjB decoy complex in 5% dextrose.
The mean diameter of the Man-liposome/NFjB decoy com-Table 1
The mean particle sizes and zeta potential of liposome and liposome
NFjB decoy complexes
Particle size (nm) Zeta potential (mV)
Man-liposome 64.6 ± 1.70 61.4 ± 0.91
Man-liposome complex 61.6 ± 1.58 54.7 ± 0.60/plex was less than 100 nm. After forming a complex with
NFjB decoy, the charge on the surface of Man-liposome/
NFjB decoy complex slightly decreased and the mean diame-
ter was not changed.
3.2. Man-liposome/NFjB decoy complex rapidly and highly
accumulated in liver after intravenous injection
Fig. 1 shows the time-courses of the radioactivity in blood,
kidney, spleen, liver, lung, muscle and heart after intravenous
injection of naked [32P] NFjB decoy or [32P] NFjB decoy
complexed with Man-liposomes or cationic liposomes. Ten
minutes after the intravenous injection of Man-liposome/[32P]
NFjB decoy complex, about 80% of the dose accumulated
in the liver. However, naked [32P] NFjB decoy was rapidly ex-
creted in the urine and gradually accumulated in the kidney.
Also, cationic liposome/[32P] NFjB decoy complex gradually
accumulated in the liver after rapid accumulation in the lung.
3.3. Man-liposome/NFjB decoy complex preferentially taken up
by NPC
After intravenous injection of Man-liposome/[32P] NFjB de-
coy complex, the radioactivity in the liver was preferentially
recovered from the NPC fraction with the radioactivity ratio
of NPC to PC (NPC/PC ratio on a cell-number basis) in the
liver being approximately 2.6 (Fig. 2). In contrast, naked
[32P] NFjB decoy had an NPC/PC ratio of 0.66 (Fig. 2) and
the cationic liposome/[32P] NFjB decoy complex had NPC/
PC ratio of 0.75 (Fig. 2). The total liver accumulation of
Man-liposome/[32P] NFjB decoy complex was higher than
that of naked [32P] NFjB decoy.
3.4. Man-liposome/NFjB decoy complex eﬀectively suppressed
inﬂammatory cytokine production
The serum concentration of TNFa was assessed using ELI-
SA to conﬁrm that NFjB decoy complexed with Man-lipo-
somes eﬀectively suppressed the production of inﬂammatory
cytokines induced by LPS in vivo (Fig. 3). After intravenous
injection of LPS, the highest serum concentration of TNFa
was observed at 1 h (data not shown). Control mice were only
treated with LPS for 1 h. A dose-dependence in the suppres-
sion eﬀect of Man-liposome/NFjB decoy complex was
observed (Fig. 3A).
Thirty micrograms of NFjB decoy complexed with Man-lip-
osomes markedly inhibited the production of TNFa in serum
compared LPS alone. However, the same amount of NFjB de-
coy complexed with cationic liposomes or Gal-liposomes could
not inhibit TNFa production (Fig. 3B). Moreover, 30 lg of a
random decoy of almost the same size but with no NFjB bind-
ing sequence had no inhibitory eﬀect on TNFa production
(Fig. 3C). These results indicated that the inhibitory eﬀect of
TNFa production depended on the sequence of the NFjB
decoy.
The serum concentrations of IL-1b and IFNc were also as-
sayed by ELISA (Fig. 4). The serum level of IL-1b and IFNc
induced by LPS was signiﬁcantly suppressed by intravenous
administration of Man-liposome/NFjB decoy complex
(Fig. 4A and B). IFNc is partly produced in response to
LPS-induced inﬂammatory cytokines (TNFa, IL-12, etc.).
Therefore, the inhibition of IFNc by Man-liposome/NFjB de-
coy complex indicated secondary inhibition following to the
inhibition of the upstream cytokines.
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Fig. 1. Blood concentration, tissue accumulation and urinary excretion of 32P-labeled naked NFjB decoy (A), cationic liposome/32P-labeled NFjB
decoy complex (B) and Man-liposome/32P-labeled NFjB decoy complex (C) after intravenous injection into mice. 32P-labeled NFjB decoy was
complexed with mannosylated liposomes or cationic liposomes at a charge ratio of 2.3:1.0 (+:). Radioactivity was determined in blood, liver, lung,
spleen, kidney, heart, muscle and urine after 1, 5, 10, 30 and 60 min. Each value represents the mean ± S.D. (n = 3). Signiﬁcant diﬀerence:
***P < 0.001, **P < 0.01, *P < 0.05 vs. (naked NFjB decoy); ###P < 0.001, ##P < 0.01, #P < 0.05 vs. (cationic liposome complexes); and
P < 0.001, P < 0.01, P < 0.05 vs. (Man-liposome complexes).
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severe liver injury
ALT or AST measured in serum provide an index of hepa-
tocyte integrity. Leakage of ALT and AST into the extracellu-
lar compartment and a subsequent rise in serum reﬂect
hepatocytes damage. These enzymes are signiﬁcantly elevated
at liver damage caused by LPS induced inﬂammatory cyto-
kines. Only LPS treatment with ICR mice did not caused sig-
niﬁcantly rise serum ALT and AST level (data not shown).
Therefore, LPS and D-(+)-galactosamine treated C57BL/6
mice were used to determine therapeutic eﬀect of Man-lipo-
some/NFjB decoy complex for liver injury. The serum activity
of ALT and AST increased after administration of LPS and D-(+)-galactosamine, which indicated severe liver injury.
Although naked NFjB decoy did not prevent liver injury,
Man-liposome/NFjB decoy complex signiﬁcantly inhibit in-
crease of ALT and AST level in the serum (Fig. 5). These re-
sults indicated Man-liposome/NFjB decoy complex could
prevent LPS caused liver injury.
3.6. Man-liposome/NFjB decoy complex eﬀectively prevents
NFjB activation in nuclei
In response to inﬂammatory stimuli, IjB protein degraded
and allowed NFjB to translocate into the nucleus to initiate
gene expression of inﬂammatory cytokines. The amount of
activated NFjB in the nuclei was measured by enzyme immu-
0 5 10 15 20
Recovery (% of dose/108 cells)
Naked NFκB decoy
Cationic liposome 
complexes
Man-liposome
complexes
NPC/PC
= 0.66
NPC/PC
= 2.6
NPC/PC
= 0.75
PC
NPC
Fig. 2. Intrahepatic distribution of 32P-labeled naked NFjB decoy, cationic liposome/32P-labeled NFjB decoy complex and Man-lipo-
some/32P-labeled NFjB decoy complex after intravenous injection into mice. 32P-labeled NFjB was complexed with mannosylated liposomes or
cationic liposomes at a charge ratio of 2.3:1.0 (+:). Radioactivity was determined in NPC (j) and PC (h). Each value represents the mean ± S.D.
(n = 3).
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liposome/NFjB decoy complex on the activation of NFjB.
After LPS treatment, the amount of activated NFjB was dra-
matically increased. However, after injection of Man-lipo-
some/NFjB decoy complex, the amount of activated NFjB
in nuclei did not increase with LPS treatment (Fig. 6).4. Discussion
Recently, new techniques to inhibit target gene expression
using oligonucleotides, such as decoy oligonucleotides, anti-
sense DNA, ribozyme and siRNA, have been developed, which
are expected to be attractive treatments without side-eﬀects on
genome DNA compared with pDNA. However, oligonucleo-
tides are easily degraded in blood and rapidly metabolized
and, therefore, potential carriers have to be developed capable
of carrying enough oligonucleotide to produce a therapeutic
eﬀect. As far as NFjB decoy therapy for endotoxin syndrome
is concerned, since Kupﬀer cells play an important role of pro-
ducing cytokines, NFjB decoy taken up by Kupﬀer cells could
eﬀectively inhibit NFjB-mediated inﬂammatory cytokine pro-
duction. In this respect, in order to achieve a therapeutic eﬀect
with NFjB decoy, it is necessary to develop a Kupﬀer cell-tar-
geting carrier for NFjB decoy. Previously, we have developed
a novel pDNA carrier system for NPC targeting involving
Man-liposomes, which could eﬀectively achieve cell-speciﬁc
transfer to NPC and macrophages in vivo and in vitro [20–
22]. Man-liposomes are an attractive tool for NFjB decoy
delivery to Kupﬀer cells, although the physicochemical proper-
ties, such as molecular weight and size, of the NFjB decoy and
pDNA are very diﬀerent. Therefore, the purpose of this study
was to investigate the distribution and therapeutic eﬀect of
Man-liposome/NFjB decoy complex on endotoxin syndrome.
To investigate NPC selective delivery of NFjB decoy by
Man-liposomes, the tissue and intrahepatic distribution of
Man-liposome/[32P] NFjB decoy complex were examined. In
this study, Man-liposome/[32P] NFjB decoy complex exhibited
rapid and high accumulation in the liver (Fig. 1). This result
was well concerned with the tissue accumulation of Man-lipo-some/pDNA complex after intravenous injection [22]. As far as
intrahepatic distribution is concerned, the Man-liposome/
NFjB decoy complex was preferentially taken up by NPC
(Fig. 2). This result also agreed with the intrahepatic distribu-
tion of Man-liposome/pDNA complex [22]. Considering that
mannose receptors are expressed on NPC [17], these results
are in good agreement with the intrahepatic distribution of
Man-liposome/NFjB decoy complex (Fig. 2). Moreover,
Gal-liposome/NFjB decoy complex could not inhibit cytokine
production, comparing to the same amount of NFjB decoy
delivered by Man-liposome showed signiﬁcantly inhibitory ef-
fect (Fig. 3B). Gal-liposome/NFjB decoy complex would be
preferentially taken up by hepatocyte not by NPC, since a
large number of asiaroglycoprotein receptor, which could rec-
ognize galactose, was expressed on hepatocyte not NPC [28].
These results supported the mannose receptor-mediated up-
take of Man-liposome/NFjB decoy complex.
To determine the therapeutic eﬀect of Man-liposome/NFjB
decoy complex, we investigated the inhibitory eﬀect on cyto-
kine production and liver injury measuring serum ALT and
AST. The inhibitory eﬀect of Man-liposome/NFjB decoy
complex on cytokine production was determined by measuring
the serum concentration of LPS-induced TNFa, which in-
duced other kinds of cytokine production and inﬂammation
(Fig. 4). Man-liposome/NFjB decoy complex signiﬁcantly
inhibited the production of these cytokines compared with
the same dose of naked NFjB decoy and bare cationic lipo-
some/NFjB decoy. Increase of serum ALT and AST, which
indicate hepatocytes injury caused by inﬂammatory cytokines,
were also prevented by Man-liposome/NFjB decoy complex
but not by naked NFjB decoy. These results suggest that
NFjB decoy is eﬀectively delivered to Kupﬀer cells by Man-
liposomes. This result agrees with the intrahepatic distribution
of Man-liposome/NFjB decoy complex after intravenous
injection (Fig. 2).
In order to evaluate whether Man-liposome/NFjB decoy
complex could inhibit NFjB-mediated transcription, the
amount of activated NFjB in the nuclei was determined by
EIA (Fig. 6). The amount of activated NFjB in the liver nuclei
was reduced by Man-liposome/NFjB decoy complex, which
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Fig. 3. Inhibitory eﬀect of Man-liposome/NFjB decoy complex on the production of TNFa at diﬀerent doses (A), several kinds of liposomes/NFjB
decoy complexes (B) and the sequence of the decoy (C). Serum concentration of TNFa was determined by ELISA. One minute after intravenous
administration of LPS, Man-liposome/NFjB decoy complex or Man-liposome/random decoy complex was intravenously injected into mice. Blood
was collected from the vena cava at 1 h. Each value represents the mean ± S.D. (n = 3, 4). Signiﬁcant diﬀerence: ***P < 0.001 vs. (LPS); ##P < 0.01 vs.
(LPS + cationic liposome complexes); P < 0.05 vs. (LPS + Gal-liposome complexes); P < 0.05 vs. (LPS + Man-liposome/random decoy complex).
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cation of NFjB into the nuclei. In addition, the production of
IFNc and IL-1b was also inhibited by the Man-liposome/
NFjB decoy complex (Fig. 4), however, TNFa production
could not be inhibited by the Man-liposome/random decoy
complex. This result suggests that the sequence of the NFjB
decoy is important for the inhibition of NFjB activation.
These results conﬁrm that NFjB decoy delivered by Man-lip-
osomes is able to inhibit NFjB-mediated transcription. Since
NFjB decoy can inhibit several kinds of NFjB-mediated cyto-
kine production at the same time, cell-speciﬁc delivery of
NFjB decoy will contribute to the novel therapy of other dis-
eases involving several kinds of inﬂammatory cytokines.
As far as the therapy of liver disease evoked cytokine pro-
duction by Kupﬀer cells is concerned, a Kupﬀer cell-targeting
carrier is required for the eﬀective therapy with NFjB decoy.To date, some carriers, including HVJ liposomes [14] and bare
cationic liposomes [13], have been used as NFjB carriers to in-
hibit Kupﬀer cell cytokine production. However, because these
carriers deliver NFjB decoy to any liver cells, the amount of
NFjB decoy delivered to Kupﬀer cells is small considering that
the number of Kupﬀer cells account for only 15% of the total
number of liver cells [17]. In our previous study of bare cat-
ionic liposomes, after intravenous injection, bare cationic lipo-
some/NFjB decoy complex gradually accumulated in the liver
after rapid accumulation in the lung [13]. This rapid accumu-
lation in the lung agreed with the distribution of cationic
liposomes [29] and cationic liposome/pDNA complex [22,30].
As far as the intrahepatic distribution of bare cationic
liposome/NFjB decoy is concerned, NPC/PC of cationic
liposome/NFjB decoy was 1/3-fold lower than that of
Man-liposome/NFjB decoy complex (Fig. 2). Considering
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Fig. 4. Inhibitory eﬀect of Man-liposome/NFjB decoy complex or Man-liposome/random decoy complex on the production of IL-1b (A) and IFNc
(B). One minute after intravenous administration of LPS, Man-liposome/NFjB decoy complex (30 lg/mouse) was intravenously injected into mice.
Blood was collected from the vena cava at 3 h (IL-1b) and 6 h (IFNc). Each value represents the mean ± S.D. (n = 3). Signiﬁcant diﬀerence: *P < 0.05
vs. (LPS in A); ##P < 0.01 vs. (LPS in B).
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Fig. 5. Inhibitory eﬀect of Man-liposome/NFjB decoy complexes on liver injury. One minute after intraperitoneal administration of LPS and D-(+)-
galactosamine, Man-liposome/NFjB decoy complex (30 lg/mouse) or naked NFjB decoy were intravenously injected into mice. Blood was collected
from the vena cava at 6 h. Serum concentration was determined in ALT (j) and AST (). Each value represents the mean ± S.D. (n = 4). Signiﬁcant
diﬀerence: *P < 0.05 vs. (LPS); #P < 0.05 vs. (LPS + naked NFjB decoy).
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of NFjB decoy delivered by bare cationic liposomes is much
lower than that by Man-liposomes. The results of this distribu-
tion study are in agreement with the pharmacological results
showing that bare cationic liposome/NFjB decoy complex
cannot suppress cytokine production while the same amount
of NFjB decoy complexed with Man-liposomes signiﬁcantly
inhibits cytokine production (Fig. 3B). These results provide
evidence that Kupﬀer cell-selective delivery is important for
prevention of cytokines production.
In the present study, we demonstrated that Kupﬀer cell-
selective delivery using Man-liposomes eﬀectively inhibits cyto-
kine production by Kupﬀer cells and liver injury caused bycytokines. Recently, we demonstrated that fucose-decorated
bovine serum albumin, as a model macromolecular compound,
was preferentially taken up by Kupﬀer cells via recognition by
fucose receptors, which are uniquely expressed on Kupﬀer cells
[31,32]. Therefore, fucose decoration of cationic liposomes
may improve Kupﬀer cell-targeting delivery for NFjB decoy
therapy. Based on the results of this study, we now intend to
investigate fucosylated cationic liposomes.
In conclusion, Man-liposome/NFjB decoy complex showed
speciﬁc accumulation in NPC and markedly suppressed the ef-
fect of NFjB-mediated inﬂammatory cytokine production and
liver injury after intravenous injection. It was shown that
NFjB decoy was delivered by Man-liposomes via mannose
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Fig. 6. Inhibitory eﬀect of Man-liposome/NFjB decoy complex on
NFjB activation in the nuclei. One minute after intravenous admin-
istration of LPS, Man-liposome/NFjB decoy complex (30 lg/mouse)
(s) or 5% dextrose (d) was intravenously injected into mice. Liver was
excised at 0.5, 1, 3, 6, 12 h and nuclear protein was extracted. Each
value represents the mean ± S.D. (n = 3). Signiﬁcant diﬀerence:
***P < 0.001, **P < 0.01.
Y. Higuchi et al. / FEBS Letters 580 (2006) 3706–3714 3713receptor recognition uptake. Following cell-speciﬁc delivery of
NFjB decoy by Man-liposomes, NFjB in the nuclei in liver
cells was attenuated and TNFa, IL1b and IFNc production
were inhibited at the same time. These observation lead us to
believe that Man-liposomes are able to contribute to the devel-
opment of new forms of therapy using oligonucleotides, such
as antisense DNA, siRNA and so on.
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